Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia
Authors:
- Laure Campillo-GimenezLCLaure Campillo-Gimenez
- Lambert AssoumouLALambert Assoumou
- Marc-Antoine ValantinMVMarc-Antoine Valantin
- Priyadharshini PajanirassaPPPriyadharshini Pajanirassa
- Juliette VillemonteixJVJuliette Villemonteix
- Cathia SouliéCSCathia Soulié
- Anne-Geneviève MarcelinAMAnne-Geneviève Marcelin
- Dominique CostagliolaDCDominique Costagliola
- Jacqueline CapeauJCJacqueline Capeau
- Brigitte AutranBABrigitte Autran
- Christine KatlamaCKChristine Katlama
- Amélie GuihotAGAmélie Guihot
- 24 April 2015
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 29 (7) , 853-856
Abstract
Immunovirological consequences of a switch to a maraviroc/raltegravir dual therapy were analyzed in 16 HIV-infected patients with persistent viral load below 50 copies/ml. At 26-week postswitch, the CD4+/CD8+ ratio decreased and the CD8+ T-cell activation increased. A decrease in classical monocytes was associated with a shift toward a proinflammatory monocyte profile and negatively correlated with ultrasensitive viral load. Thus, this therapeutic switch induced a proinflammatory profile probably driven by a slight loss of virus control.Keywords
This publication has 24 references indexed in Scilit:
- HIV-Associated Lipodystrophy: Impact of Antiretroviral TherapyDrugs, 2013
- Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trialJournal of Antimicrobial Chemotherapy, 2013
- Residual Immune Dysregulation Syndrome in Treated HIV infection2013
- Body composition changes after switching from protease inhibitors to raltegravirAIDS, 2012
- HIV Infection, Inflammation, Immunosenescence, and AgingAnnual Review of Medicine, 2011
- Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT TrialHIV Research & Clinical Practice, 2011
- HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsNature Medicine, 2010
- Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsThe Lancet, 2010
- HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidityBMJ, 2009
- Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006HIV Medicine, 2008